Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
GERN > SEC Filings for GERN > Form 8-K on 7-Dec-2012All Recent SEC Filings

Show all filings for GERON CORP | Request a Trial to NEW EDGAR Online Pro

Form 8-K for GERON CORP


7-Dec-2012

Other Events


Item 8.01 Other Events.

On September 30, 2002, Geron Corporation ("Geron") and Asia Biotech Company, Limited, entered into a Commercial License Agreement, as amended November 14, 2006 (the "License Agreement"), pursuant to which Asia Biotech Company, Limited obtained an exclusive license to certain intellectual property of Geron related to telomerase activation technology, for the development of dietary food supplements, nutraceuticals, and topically applied cosmetics and cosmeceuticals.

On December 5, 2012, Geron, Asia Biotech Corp. (as successor-in-interest to Asia Biotech Company, Limited) ("Asia Biotech") and Telomerase Activation Sciences, Inc. ("TA Sciences") entered into a Termination and Assignment Agreement (the "Termination Agreement"), pursuant to which Geron and Asia Biotech agreed to terminate the License Agreement, and Geron agreed to assign to TA Sciences certain intellectual property, including patents previously licensed to Asia Biotech under the License Agreement, related to telomerase activation technology and owned or controlled by Geron.

As a condition to closing, Asia Biotech and TA Sciences will remove all references to Geron from all on-line materials of Asia Biotech and TA Sciences. In consideration for the obligations set forth in the Termination Agreement, TA Sciences will pay to Geron a non-refundable, upfront termination and assignment fee of $2.5 million, due within three business days of the confirmed removal of Geron's name from all on-line Asia Biotech and TA Sciences materials. After an initial forty-five day technology transfer period, Geron will no longer work with Asia Biotech and TA Sciences in any area, and Asia Biotech and TA Sciences will have removed all references to Geron from any on-line and printed marketing material of Asia Biotech and TA Sciences. Asia Biotech and TA Sciences are permitted to state that the telomerase activation technology assigned by Geron was originally discovered and patented by Geron Corporation.

The assignment of intellectual property will be effective upon removal by Asia Biotech and TA Sciences of all references to Geron from all on-line material, and after confirmation by Geron of such removal.


  Add GERN to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for GERN - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2013 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.